Literature DB >> 22173980

Comparative full genome analysis of four infectious laryngotracheitis virus (Gallid herpesvirus-1) virulent isolates from the United States.

S J Spatz1, J D Volkening, C L Keeler, G F Kutish, S M Riblet, C M Boettger, K F Clark, L Zsak, C L Afonso, E S Mundt, D L Rock, M Garcia.   

Abstract

Gallid herpesvirus-1 (GaHV-1), commonly named infectious laryngotracheitis (ILT) virus, causes the respiratory disease in chickens known as ILT. The molecular determinants associated with differences in pathogenicity of GaHV-1 strains are not completely understood, and a comparison of genomic sequences of isolates that belong to different genotypes could help identify genes involved in virulence. Dideoxy sequencing, 454 pyrosequencing and Illumina sequencing-by-synthesis were used to determine the nucleotide sequences of four genotypes of virulent strains from GaHV-1 groups I-VI. Three hundred and twenty-five open reading frames (ORFs) were compared with those of the recently sequenced genome of the Serva vaccine strain. Only four ORFs, ORF C, U(L)37, ICP4 and U(S)2 differed in amino acid (aa) lengths among the newly sequenced genomes. Genome sequence alignments were used to identify two regions (5' terminus and the unique short/repeat short junction) that contained deletions. Seventy-eight synonymous and 118 non-synonymous amino acid substitutions were identified with the examined ORFs. Exclusive to the genome of the Serva vaccine strain, seven non-synonymous mutations were identified in the predicted translation products of the genes encoding glycoproteins gB, gE, gL and gM and three non-structural proteins U(L)28 (DNA packaging protein), U(L)5 (helicase-primase) and the immediate early protein ICP4. Furthermore, our comparative sequence analysis of published and newly sequenced GaHV-1 isolates has provided evidence placing the cleavage/packaging site (a-like sequence) within the inverted repeats instead of its placement at the 3' end of the U(L) region as annotated in the GenBank's entries NC006623 and HQ630064.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173980     DOI: 10.1007/s11262-011-0696-3

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  47 in total

1.  Consed: a graphical tool for sequence finishing.

Authors:  D Gordon; C Abajian; P Green
Journal:  Genome Res       Date:  1998-03       Impact factor: 9.043

2.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

3.  A microRNA of infectious laryngotracheitis virus can downregulate and direct cleavage of ICP4 mRNA.

Authors:  Lisa A Waidner; Joan Burnside; Amy S Anderson; Erin L Bernberg; Marcelo A German; Blake C Meyers; Pamela J Green; Robin W Morgan
Journal:  Virology       Date:  2011-01-12       Impact factor: 3.616

4.  Analysis of the nucleotide sequence of DNA from the region of the thymidine kinase gene of infectious laryngotracheitis virus; potential evolutionary relationships between the herpesvirus subfamilies.

Authors:  A M Griffin; M E Boursnell
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

5.  DNA sequence of the UL6 to UL20 genes of infectious laryngotracheitis virus and characterization of the UL10 gene product as a nonglycosylated and nonessential virion protein.

Authors:  Walter Fuchs; Thomas C Mettenleiter
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

6.  Gene arrangement within the unique long genome region of infectious laryngotracheitis virus is distinct from that of other alphaherpesviruses.

Authors:  K Ziemann; T C Mettenleiter; W Fuchs
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Differentiation of infectious laryngotracheitis virus isolates by restriction fragment length polymorphic analysis of polymerase chain reaction products amplified from multiple genes.

Authors:  Naomi C Kirkpatrick; Alireza Mahmoudian; Denise O'Rourke; Amir H Noormohammadi
Journal:  Avian Dis       Date:  2006-03       Impact factor: 1.577

8.  The nucleotide sequence of the glycoprotein gB gene of infectious laryngotracheitis virus: analysis and evolutionary relationship to the homologous gene from other herpesviruses.

Authors:  A M Griffin
Journal:  J Gen Virol       Date:  1991-02       Impact factor: 3.891

9.  Use of lambda gt11 and monoclonal antibodies to map the gene for the 60,000 dalton glycoprotein of infectious laryngotracheitis virus.

Authors:  K Kongsuwan; M A Johnson; C T Prideaux; M Sheppard
Journal:  Virus Genes       Date:  1993-09       Impact factor: 2.332

10.  Nucleotide sequence of infectious laryngotracheitis virus (gallid herpesvirus 1) ICP4 gene.

Authors:  M A Johnson; S G Tyack; C Prideaux; K Kongsuwan; M Sheppard
Journal:  Virus Res       Date:  1995-02       Impact factor: 3.303

View more
  13 in total

Review 1.  Infectious laryngotracheitis virus in chickens.

Authors:  Shan-Chia Ou; Joseph J Giambrone
Journal:  World J Virol       Date:  2012-10-12

2.  Retrospective analysis of infectious laryngotracheitis in backyard chicken flocks in California, 2007-2017, and determination of strain origin by partial ICP4 sequencing.

Authors:  Julia Blakey; Simone Stoute; Beate Crossley; Aslı Mete
Journal:  J Vet Diagn Invest       Date:  2019-04-11       Impact factor: 1.279

3.  Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges.

Authors:  Wei Zhao; Stephen Spatz; Zhenyu Zhang; Guoyuan Wen; Maricarmen Garcia; Laszlo Zsak; Qingzhong Yu
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

4.  Single Nucleotide Polymorphism Genotyping Analysis Shows That Vaccination Can Limit the Number and Diversity of Recombinant Progeny of Infectious Laryngotracheitis Viruses from the United States.

Authors:  Maricarmen García; Joanne M Devlin; Carlos A Loncoman; Carol A Hartley; Mauricio J C Coppo; Glenn F Browning; Gabriela Beltrán; Sylva Riblet; Carolina O Freitas
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

5.  Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence.

Authors:  Evin Hildebrandt; John R Dunn; Sudeep Perumbakkam; Masahiro Niikura; Hans H Cheng
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

6.  Multiple Comparison Analysis of Two New Genomic Sequences of ILTV Strains from China with Other Strains from Different Geographic Regions.

Authors:  Yan Zhao; Congcong Kong; Yunfeng Wang
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

7.  Full Genome Sequence-Based Comparative Study of Wild-Type and Vaccine Strains of Infectious Laryngotracheitis Virus from Italy.

Authors:  Alessandra Piccirillo; Enrico Lavezzo; Giulia Niero; Ana Moreno; Paola Massi; Elisa Franchin; Stefano Toppo; Cristiano Salata; Giorgio Palù
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

8.  Molecular Characterization and Cluster Analysis of Field Isolates of Avian Infectious Laryngotracheitis Virus from Argentina.

Authors:  María I Craig; Maria F Rojas; Claudia A van der Ploeg; Valeria Olivera; Ariel E Vagnozzi; Andrés M Perez; Guido A König
Journal:  Front Vet Sci       Date:  2017-12-13

9.  Complete genome sequence of the first Chinese virulent infectious laryngotracheitis virus.

Authors:  Congcong Kong; Yan Zhao; Xianlan Cui; Xiaomin Zhang; Hongyu Cui; Mei Xue; Yunfeng Wang
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Phylogenetic and molecular epidemiological studies reveal evidence of multiple past recombination events between infectious laryngotracheitis viruses.

Authors:  Sang-Won Lee; Joanne M Devlin; John F Markham; Amir H Noormohammadi; Glenn F Browning; Nino P Ficorilli; Carol A Hartley; Philip F Markham
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.